2015
Does “two is better than one” apply to surgeons? Comparing single-surgeon and cosurgeon bilateral mastectomy outcomes.
Nimbkar S, Mallory M, Losk K, Camuso K, Golshan M. Does “two is better than one” apply to surgeons? Comparing single-surgeon and cosurgeon bilateral mastectomy outcomes. Journal Of Clinical Oncology 2015, 33: 35-35. DOI: 10.1200/jco.2015.33.28_suppl.35.Peer-Reviewed Original ResearchOverall surgery timeSingle surgeonBilateral mastectomyTotal breast weightSurgery timeBreast weightCS casesTissue expander reconstructionStage of cancerAlternative operative approachAxillary dissectionAxillary procedurePostoperative complicationsComplication rateMedical chartsPatient ageOperative recordsUnilateral mastectomyExpander reconstructionBreast surgeonsSurgical timeOperative approachPatient outcomesBivariate analysisLarger study
2013
Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology.
Losk K, Kadish S, Golshan M, Lin N, Hirshfield-Bartek J, Cutone L, Bunnell C, Weingart S. Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology. Journal Of Clinical Oncology 2013, 31: 51-51. DOI: 10.1200/jco.2013.31.31_suppl.51.Peer-Reviewed Original ResearchInitiation of chemotherapyBreast cancer patientsMedical oncologyOncology followDefinitive surgeryCancer patientsConsecutive breast cancer patientsChemotherapy treatment delaysAdverse clinical outcomesBreast cancer careTransitions of careProcess of careAdjuvant chemotherapyTimely chemotherapyMedical oncologistsClinical outcomesTreatment delayBreast surgeryCancer careInitial consultationBreast surgeonsCare coordinationChemotherapySurgeryMultidisciplinary teamImpact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.Peer-Reviewed Original ResearchNeoadjuvant therapyBCT candidatesCALGB 40601Neoadjuvant chemotherapySystemic therapySurgical resultsBreast surgeonsBreast cancerTumor-free surgical marginsBreast cancer ptsNeoadjuvant systemic therapyOperable breast cancerBreast conservation ratesPhase III trialsAnti-HER2 treatmentModern systemic therapyBreast cancer operationsBCT eligibilityCancer ptsEligible patientsNeoadjuvant trialsTherapy ratesIII trialsSurgical marginsCancer operations